Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov-Dec;35(6):1687-1690.
doi: 10.12669/pjms.35.6.990.

Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy

Hina Loya  1 , Hunain Ghoghari  2 , Syed Fawad Rizvi  3 , Abdullah Khan  4
Affiliations

Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy

Hina Loya et al. Pak J Med Sci. 2019 Nov-Dec.

Abstract

Objective: To study the effect of reducing the duration of rifampicin therapy in the treatment of Chronic Central Serous Chorioretinopathy.

Methods: This is interventional study conducted in Layton Rahmatullah Benevolent Trust, Free Base Eye Hospital Korangi, Karachi from February 2017 - December 2018. This randomized controlled comparative study included two groups, Groups-A comprised of 48 eyes of 40 cases with Chronic Central Serous Chorioretinopathy who were given reduced dose of oral rifampicin i.e. 600mg for one month, and Group-B consisted of 43 eyes of 40 controls with Chronic Central Serous Chorioretinopathy who were given reduced dose of oral rifampicin i.e. 300mg once daily for three months as previously stated in literature. To access the effect of therapy in both the groups, pre-treatment visual acuity on the logMAR and Optical Coherent Tomography (OCT, Heidelberg spectralis) for CMT were performed and repeated on the 1st and 3rd month post-treatment. Patients were also followed for 6 months to access any recurrence.

Results: On comparing the two groups, Group-A had improvement in VA and CMT after one month therapy of Rifampicin, Pre-treatment mean VA in Group-A was 0.85 ± 0.19 as compared to the pre-treatment mean VA in Group-B i.e. 0.74+/- 0.208, while the pre-treatment mean CMT was 609.0 ± 178.29 µm in Group-A, and 600.0 +/- 155.09 µm in Group-B respectively. After 1 month of therapy, the visual status, and CMT in Group-A was 0.29+/- 0.21 and 311.6 +/- 89.9, while Group-B, VA was 0.598 +/- 0.23 (p value 0.001%) and CMT was 512.30 +/- 148.37 (p-value 0.001%). Rifampicin was continued in Group-B till three months, and patients were re-accessed but there was no difference in VA and CMT statically. During the 3rd and 6th months of follow up no relapses were reported.

Conclusion: This comparative study showed that the group receiving oral rifampicin 600mg for one month showed better outcome at one month and third month than the group receiving oral rifampicin at a dose of 300mg once daily for three months. This gives a better compliance and lower the risk of drug induced side effects.

Keywords: Central macular thickness (CMT); Chronic central serous chorioretinopathy (CSCR); Optical coherence tomography (OCT); Rifampicin; Visual acuity (VA).

PubMed Disclaimer

References

    1. Araki T, Ishikawa H, Iwahashi C, Niki M, Mitamura Y, Sugimoto M, et al. Central serous chorioretinopathy with and without steroids:A multicenter survey. PloS One. 2019;14(2):e0213110. - PMC - PubMed
    1. Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic–parasympathetic activity and reactivity in central serous chorioretinopathy:a case–control study. Invest Ophthalmol Vis Sci. 2006;47(8):3474–3478. doi:10.1167/iovs.05-1246. - PubMed
    1. Wang M, Munch IC, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126–145. doi:10.1111/j.1600-0420-.2007.00889.x. - PubMed
    1. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota 1980-2002. J Ophthal. 2008;115(1):169–173. doi:10.1016/j.ophtha.2007.02.032. - PubMed
    1. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol. 2011;22(3):166–173. doi:10.1097/ICU.0b013e3283459826. - PubMed

LinkOut - more resources